Physician profile
Scott H Brown
NPI 1366402448
$4,692.36
in general payments reported to CMS, 2019-2025
32 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,041 · 2020: $691 · 2021: $971 · 2022: $736 · 2023: $621 · 2024: $416 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,253.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $938.74 | 2019-2025 | Repatha, Prolia, Evenity |
| Abbott Laboratories | $623.64 | 2021-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $603.62 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $279.54 | 2019-2023 | |
| Glaxosmithkline, LLC. | $255.84 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $247.55 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $187.71 | 2019-2023 | Eliquis |
| Amarin Pharma, INC. | $183.24 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.20 | 2019-2023 | Jardiance |
| Lilly USA, LLC | $114.20 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.78 | 2020-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $101.22 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $91.71 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $85.49 | 2019-2025 | Wegovy |
| Arbor Pharmaceuticals, INC. | $83.74 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $82.95 | 2020-2024 | |
| Shield Therapeutics INC | $77.03 | 2023-2024 | Accrufer |
| Merck Sharp & Dohme LLC | $72.64 | 2019-2021 | |
| Allergan, INC. | $63.93 | 2019-2020 | |
| Nevro Corp. | $44.39 | 2022-2024 | Senza |
| Genentech USA, INC. | $39.27 | 2019-2021 | |
| Dexcom, INC. | $36.27 | 2023-2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $34.44 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.06 | 2021 | |
| Livanova USA, INC. | $24.47 | 2020 | |
| Boston Scientific Corporation | $18.57 | 2022 | |
| Esperion Therapeutics, INC. | $16.62 | 2021 | |
| Astellas Pharma US INC | $15.98 | 2022 | |
| Nabriva Therapeutics, Plc | $15.24 | 2020 | |
| Sunovion Pharmaceuticals INC. | $14.18 | 2021 | |
| Ironwood Pharmaceuticals, INC | $14.17 | 2023 | Linzess |
| Eisai INC. | $12.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.